Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 5Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Other neoplasm 1Lymphoid 1Classical hematology 1Breast 1

Conditions

Lymphoma 1Inflammatory Bowel Diseases 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

Rituximab 1401Cyclophosphamide 1305Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 469Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 260ibrutinib 258obinutuzumab 235Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infliximab × Lymphoid × Clear all
NCT01804166 2025-02-04

A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)

Janssen Scientific Affairs, LLC

Phase 4 Completed
1 enrolled 1 chart
Lymphoid

Colitis, Ulcerative, Crohn Disease, Lymphoma, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡